ArticleMedical science monitor : international medical journal of experimental and clinical research2026
Diagnostic Concordance and Superiority of Flow Cytometry Over Immunohistochemistry in Acute Leukemia Immunophenotyping: A Single-Center Study.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Early diagnosis is crucial for effective treatment and management of acute leukemia. Flow cytometry (FC) is a fast and reliable immunophenotyping technique. This study aimed to compare the diagnostic agreement between FC and histopathological evaluation using shared parameters from bone marrow samples. MATERIAL AND METHODS A total of 144 patients presenting to Adult Hematology, Pediatric Hematology, and Pediatric Oncology clinics at Çukurova University Faculty of Medicine were enrolled; bone marrow samples were processed at the Central Laboratory FC Unit. The cohort included 70 patients with acute myeloid leukemia, 59 with B-cell acute lymphoblastic leukemia, and 15 with T-cell acute lymphoblastic leukemia. The chi-square test, Cohen's kappa, adjusted kappa coefficient, sensitivity, specificity, and accuracy were used to assess FC-IHC concordance. RESULTS The concordance between FC and immunohistochemistry (IHC) was 82.6% for AML (P>0.999, PABAK=0.99) and 61.0% for B-ALL (P=0.054, PABAK=0.89). FC achieved 95% sensitivity for AML and 100% for B-ALL. CD33, MPO, and CD117 showed significant concordance in AML, with sensitivities of 94%, 91%, and 90%, respectively. CD34 was the top-performing biomarker for AML, with 93% sensitivity and 95% specificity. For B-ALL, TdT, CD33, and CD34 showed sensitivities of 77%, 75%, and 81%, respectively. CONCLUSIONS FC showed higher concordance with IHC in AML than in B-ALL and better diagnostic sensitivity for leukemic lineage classification. CD33, MPO, and CD117 were strong AML markers, while TdT, CD33, and CD34 were effective for B-ALL. To quantitatively analyze marker expression with high sensitivity, precise lineage differentiation, and a quick turnaround time, same-day reporting and rapid initiation of targeted therapy make FC essential in modern hematopathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.